E.M. Guerra

1.8k total citations
8 papers, 77 citations indexed

About

E.M. Guerra is a scholar working on Oncology, Reproductive Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, E.M. Guerra has authored 8 papers receiving a total of 77 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 5 papers in Reproductive Medicine and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in E.M. Guerra's work include Ovarian cancer diagnosis and treatment (5 papers), PARP inhibition in cancer therapy (3 papers) and HER2/EGFR in Cancer Research (2 papers). E.M. Guerra is often cited by papers focused on Ovarian cancer diagnosis and treatment (5 papers), PARP inhibition in cancer therapy (3 papers) and HER2/EGFR in Cancer Research (2 papers). E.M. Guerra collaborates with scholars based in Spain, United States and Italy. E.M. Guerra's co-authors include Antonio González-Martı́n, Andrés Redondo, José Alejandro Pérez Fidalgo, Maria-Pilar Barretina-Ginesta, Luís Manso, María Jesús Rubio, Cristina Martín-Lorente, Ana Santaballa, Jerónimo Martínez-García and Yolanda García García and has published in prestigious journals such as Annals of Oncology, Multiple Sclerosis and Related Disorders and ESMO Open.

In The Last Decade

E.M. Guerra

8 papers receiving 77 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
E.M. Guerra Spain	4	43	36	26	13	11	8	77
María Jesús Rubio-Pérez Spain	6	86 2.0×	80 2.2×	31 1.2×	15 1.2×	21 1.9×	15	137
Simona Ruisi Italy	2	36 0.8×	36 1.0×	19 0.7×	3 0.2×	20 1.8×	2	71
Celeste Leigh Pearce Australia	4	18 0.4×	35 1.0×	63 2.4×	20 1.5×	8 0.7×	5	101
Angela Jain United States	4	23 0.5×	35 1.0×	20 0.8×	3 0.2×	5 0.5×	14	68
Vasudha Sehgal United States	5	100 2.3×	36 1.0×	69 2.7×	6 0.5×	8 0.7×	6	125
Charlotte Tyson United Kingdom	5	29 0.7×	27 0.8×	23 0.9×	32 2.5×	3 0.3×	7	85
Lindsey Beffa United States	5	10 0.2×	34 0.9×	30 1.2×	10 0.8×	5 0.5×	16	92
Maria P. Intermaggio United States	3	46 1.1×	30 0.8×	52 2.0×	60 4.6×	10 0.9×	3	119
Silvia Tore Italy	5	21 0.5×	25 0.7×	40 1.5×	15 1.2×	4 0.4×	8	94
David Chesla United States	5	15 0.3×	49 1.4×	46 1.8×	9 0.7×	15 1.4×	6	125

Countries citing papers authored by E.M. Guerra

Since Specialization

Citations

This map shows the geographic impact of E.M. Guerra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E.M. Guerra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E.M. Guerra more than expected).

Fields of papers citing papers by E.M. Guerra

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E.M. Guerra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E.M. Guerra. The network helps show where E.M. Guerra may publish in the future.

Co-authorship network of co-authors of E.M. Guerra

This figure shows the co-authorship network connecting the top 25 collaborators of E.M. Guerra. A scholar is included among the top collaborators of E.M. Guerra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E.M. Guerra. E.M. Guerra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Tavazzi, Eleonora, et al.. (2022). Quantitative and qualitative features of acute phase-adverse events following SARS-CoV-2 vaccination in a large sample of people with multiple sclerosis. Multiple Sclerosis and Related Disorders. 68. 104120–104120. 2 indexed citations

Redondo, Andrés, E.M. Guerra, Luís Manso, et al.. (2021). SEOM clinical guideline in ovarian cancer (2020). Clinical & Translational Oncology. 23(5). 961–968. 29 indexed citations

Fidalgo, José Alejandro Pérez, Alfonso Cortés, E.M. Guerra, et al.. (2021). Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study). ESMO Open. 6(4). 100212–100212. 23 indexed citations

Saavedra, Cristina, et al.. (2021). 121P Impact of HER2 low (H2L) expression on prognosis in luminal locally advanced or metastatic breast cancer (BC): A retrospective study. Annals of Oncology. 32. S73–S73. 1 indexed citations

Graybill, Whitney A. Spannuth, Mansoor Raza Mirza, Antonio González-Martı́n, et al.. (2020). 13 Efficacy on individualized starting dose (ISD) and fixed starting dose (FSD) of niraparib per investigator-assessment (IA) in newly diagnosed advanced ovarian cancer (OC). A10.1–A10. 3 indexed citations

Miranda, Elena, et al.. (2019). Efficacy of trastuzumab-emtansina (T-DM1) in HER2-positive breast cancer (BC) with brain metastases (BM): A single institution experience. Annals of Oncology. 30. iii60–iii60. 1 indexed citations

Santaballa, Ana, Maria-Pilar Barretina-Ginesta, Antonio Casado, et al.. (2016). SEOM Clinical Guideline in ovarian cancer (2016). Clinical & Translational Oncology. 18(12). 1206–1212. 17 indexed citations

Berton-Rigaud, Dominique, Joachim Alexandre, Magali Provansal, et al.. (2012). Lurbinectedin (PM01183) Activity in Platinum-Resistant/Refractory Ovarian Cancer Patients. Preliminary Results of an Ongoing Two-Stage Phase II Study. Annals of Oncology. 23. ixe17–ixe17. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact